ARA-290 (Cibinetide)
ARA-290 and cibinetide are names used in an engineered peptide research programme derived from erythropoietin-related work. Match the complete structure and terminal chemistry before treating an alias on a certificate as a verified material identity.
Reference origin
Brines and colleagues' 2008 study described an 11-residue surface-derived design and distinguished its peptide constructs from full erythropoietin. That experimental origin does not make ARA-290 chemically equivalent to EPO or establish a medicine status for a research container. [1]
| Identity field | Record to reconcile |
|---|---|
| Canonical entity and alias | ARA-290/cibinetide naming in the actual source |
| Sequence and terminal chemistry | Complete defined construct |
| Registry identifier | Identifier matching the specified entity and form |
| Supplied composition | Salt, physical form and relevant other constituents |
| Quantity basis | Meaning of the nominal amount |
| Lot result | Sample and method supporting the stated identity |
Different studies answer different questions
The 2012 sarcoidosis pilot involved 22 participants and reported different patterns across symptom measures. Improvements in pain and fatigue measures were equivalent between groups, so the study should not be reduced to an unqualified pain-efficacy claim. [3]
The later cibinetide trial distinguished corneal nerve-fibre area from pain. The pain comparison was not statistically significant. A finding in a structural biomarker cannot stand in for a demonstrated symptom benefit. [2]
A separate diabetes-related study reported a corneal-density finding in a low-baseline-density subgroup. That restriction belongs with the result. [4]
Follow the research lineage without importing an indication
The innate repair receptor guide traces the earlier EPO/CEPO receptor experiments and subsequent peptide design. Those stages should not be collapsed into one universal mechanism or a claim that all published preparations match the current product.
The ARA-290 10 mg listing owns the commercial presentation. Request its exact identity, amount basis and lot-matched documentation through batch records. No therapeutic indication, administration guidance or clinical equivalence is established by the alias alone.
Continue the material check
| Resource | Why open it |
|---|---|
| Receptor-Targeted Research Peptides | Browse receptor-related materials with variant limits visible. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Receptor Agonists and Selectivity | Read binding, potency, efficacy and selectivity in context. |
| Product Specification and Identity Standards | Check which tests, criteria and quantity basis a specification defines. |
The Certificate of Analysis guide helps check whether the supplied report concerns the same material and lot as the container.
Sources and scope
- Brines et al. (2008). Helix-B-derived nonerythropoietic peptides. PNAS.11-residue surface design; pHBSP, HBP and full EPO kept distinct. No dose or administration instructions copied. Access: Original abstract plus accessible full original article
- Culver et al. (2017). Cibinetide, nerve measurements and pain endpoints. IOVS.Only middle dose meets primary significance; pain comparison p=0.157 not significant; surrogate versus symptoms separated. Access: Original article abstract retrieved through official Europe PMC core record
- Heij et al. (2012). ARA-290 sarcoidosis pilot. Molecular Medicine.22-person pilot; symptom-list response versus placebo, BPI/fatigue improvements equivalent between groups. Access: Original abstract plus publisher/PMC Results passages opened
- Brines et al. (2015). ARA-290 in type 2 diabetes and neuropathy. Molecular Medicine.28-day intervention/56-day observation; corneal density finding restricted to low-baseline-density subgroup. No exact participant count inferred from abstract. Access: Original article abstract retrieved through official Europe PMC core record